About Neuren Pharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) is an Australian-based pharmaceutical company that develops and commercialises new drugs for the treatment of central nervous system (CNS) disorders. The company's flagship asset is NNZ-2566, a drug candidate for the treatment of Fragile X syndrome, a rare genetic disorder that causes intellectual disability. Neuren is also developing a number of other drug candidates for the treatment of other CNS disorders, including Parkinson's disease, Huntington's disease, and Alzheimer's disease. Neuren's operations are focused on the development and commercialization of new drugs for CNS disorders. The company has a number of drug candidates in clinical trials, and is also working on the development of new preclinical drug candidates.
Snapshot
Operations
Produtos e/ou serviços de Neuren Pharmaceuticals
- Developing Trofintide (NEP1492), an investigational drug for the treatment of Rett syndrome and Fragile X syndrome.
- Developing NNZ-2566, an investigational drug for the treatment of Angelman syndrome.
- Developing NNZ-529, an investigational drug for the treatment of Parkinson's disease.
- Developing new drugs for the treatment of nervous system disorders.
- Conducting clinical trials to evaluate the safety and efficacy of its investigational drugs.
- Seeking regulatory approval for its investigational drugs.
equipe executiva do Neuren Pharmaceuticals
- Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A.CEO, MD & Executive Director
- Ms. Lauren Frazer C.A.CFO & Company Secretary
- Dr. Clive Blower BSc (Hons), Ph.D.Chief Operations Officer
- Mr. Lawrence Glass BA (Biology)Chief Science Officer
- Mr. Gerry ZhaoChief Business Officer
- Dr. Liza A. Squires M.D.Chief Medical Officer
- Mr. Daryl DekarskeChief Regulatory Officer